Fosun Pharmaceutical 2196

Re: Fosun Pharmaceutical 2196

Postby winston » Fri Nov 04, 2016 10:49 am

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. -------------- Maintain OUTPERFORM
Notes from the CIC: Pharmaceutical and hospital businesses are the major growth drivers

Fosun Pharma attended the CIC on 2 November. Management highlighted that the company had a strong 3Q16, mainly driven by the fast growth in the pharmaceutical and hospital businesses.

The gross margin increased by 3% pp in 1-3Q16. The growth of high-margin products, such as Youdier and Youlitong, is accelerating, thanks to winning tenders in additional provinces.

Management expects the gross margin to continue to increase for new product launches, e.g. Rituxan biosimilar in 2018E and Herceptin biosimilar in 2019E.

Hospital business is expected to maintain fast growth, given the supply shortage of high-quality healthcare services in China.

The company’s strategy is to collaborate with renowned local hospitals to expand this business.

Management guides company net profit growth in 2017 will be no less than 13%. We believe upside in its pharmaceutical pipeline and strong operation capabilities in hospitals are not fully priced inyet. Maintaining our OUTPERFORM rating.

Source: CS
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Mon Nov 28, 2016 9:40 am

not vested

FOSUN PHARMA (02196.HK) Parent Company Raises Stake to 38.46%

FOSUN PHARMA (02196.HK) announced that from 24 to 25 November, Fosun Group acquired an aggregate number of 632,500 H Shares through the trading system of Shanghai Stock Exchange Shanghai-Hong Kong Stock Connect, at the average price of approximately $24.54 per share for an aggregate amount of approximately $15.52 million.

After the shareholding Increase, Fosun Group holds 926 million A Shares and 2.418 million H shares, representing approximately 38.46% of the total issued shares.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Wed Mar 29, 2017 10:39 am

not vested

<Result Ann>FOSUN PHARMA (02196.HK) Annual Net Profit RMB2.806B; Div 35 Fen

FOSUN PHARMA (02196.HK) announced the results for the year ended 2016.

Net profit added 14.1% to RMB2.806 billion, with EPS of RMB1.21.

Dividend was 35 fen.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Wed May 17, 2017 9:38 am

It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Mon Sep 11, 2017 8:40 am

not vested

Fosun Pharmaceutical wants to be the Xiaomi of China’s drug industry

With a focus on overseas emerging markets, Fosun Pharma wants to challenge western rivals the same way Xiaomi did with Apple in smartphones

“We can produce drugs that meet European Union standards but with a much cheaper price, which is our competitive edge”.

China is the second largest pharmaceutical markets in the world, and is forecast to grow from US$108 billion in 2015 to US$167 billion by 2020, representing annual growth of 9.1 per cent


Source: SCMP

http://www.scmp.com/business/china-busi ... g-industry
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Tue Jul 28, 2020 3:42 pm

not vested

May 3, 2020

<Result Ann>FOSUN PHARMA 1Q NP Sinks 19% to RMB577M

FOSUN PHARMA (02196.HK) unveiled the 2020 first quarterly report.

It recorded a net profit of RMB577 million, down 19% yearly, with an EPS of 23 fen.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Wed Aug 26, 2020 1:12 pm

vested

<Result Ann>FOSUN PHARMA (02196.HK) Interim NP RMB1.715B, Up 13.1%; Nil Div

FOSUN PHARMA (02196.HK) announced the interim results ended 30 June 2020.

Net profit grew 13.1% yearly to RMB1.715 billion.

EPS equaled 67 fen.

No interim dividend was declared.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Thu Aug 27, 2020 8:20 am

vested

Shanghai’s Fosun Pharma on track to bring German partner’s Covid-19 vaccine to China by year-end

Fosun earlier obtained the licence from Mainz-based BioNTech to exclusively develop and commercialise its mRNA Covid-19 vaccine products in China

Fosun has dosed 72 volunteers with BioNTech’s vaccine in a phase-one trial in Jiangsu province, and the preliminary safety data are ‘good’, said CEO Wu Yifang

by Eric Ng

“Pfizer and BioNTech recently said they are on track to seek regulatory review on the BNT162b2 vaccine candidate as early as October this year. If it is approved, we hope to be able to follow suit in Greater China soon.”

They plan to supply up to 100 million doses worldwide by the end of this year and 1.3 billion by the end of 2021.

Unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence – the molecule which tells cells what to build – which is coded for antigens, the proteins that resemble that of the pathogen.

Once produced within the body, the antigen on coronavirus-infected cells is recognised by the immune system which can then fight them.

RNA vaccines are faster and cheaper to produce than traditional vaccines, and an RNA-based vaccine is also safer for the patient as they are not produced using infectious elements, according to health care think tank PHG Foundation, part of the UK’s University of Cambridge.

Fosun Pharma on Tuesday posted a 13 per cent year-on-year rise in net profit to 1.7 billion yuan in the first half of 2020, as revenue decreased 0.9 per cent to 14 billion yuan.

It attributed the profit rise to sales of Covid-19 test kits and life-support ventilators, as well as drugs for treating gout, depression, blood cancers and reducing blood cholesterol.

It was also lifted by a 52 per cent profit growth at its India generic drugs subsidiary, Gland Pharma, which Fosun is aiming to separately list in Mumbai by year-end, Wu said.


Source: SCMP

https://www.scmp.com/business/companies ... s-covid-19
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Fri Aug 28, 2020 9:07 am

vested

FOSUN PHARMA, BioNTech Supply 10M Doses mRNA-based COVID-19 Vaccine to HK, MO

FOSUN PHARMA (02196.HK) and BioNTech SE (BNTX.US) jointly announced for an intended collaboration to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, to Hong Kong and Macao SARs

Fosun Industrial Co., Limited, a wholly owned subsidiary of FOSUN PHARMA, entered into the Letter of Intent with JACOBSON PHARMA (02633.HK) in relation to the contemplated distribution of 10 million doses of vaccine targeting at COVID-19 in the Region on 27 August.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

Re: Fosun Pharmaceutical 2196

Postby winston » Mon Aug 31, 2020 1:33 pm

vested

Shanghai Fosun Pharmaceutical Group (2196 HK / 600196 CH) - Decent earnings

Established in 1994, Shanghai Fosun Pharma is an integrated healthcare group in China offering pharmaceutical products, medical devices and healthcare services via its hospital network.

Its vision is to become a first tier enterprise in the global mainstream pharmaceutical and healthcare market.

Fosun’s pharmaceutical portfolio contributed ~76% of 2019 revenues, while other key contributing segments were medical devices and healthcare services.

In terms of geography, ~77% of its FY19 revenues was derived from China.

While Fosun provides medium term exposure to China’s growing demand for healthcare driven by increasing disposable income and aging population trends, near term factors which may influence share price performance include market expectations for pricing pressure from ongoing healthcare sector reforms (which should resume in 2H20) and higher expenses relating to its R&D and growth plan.

HOLD (2196 HK) / SELL (600196 CH).

Source: OCBC
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118528
Joined: Wed May 07, 2008 9:28 am

PreviousNext

Return to D to K

Who is online

Users browsing this forum: No registered users and 8 guests

cron